>>do something else with your weekend<<
Naturally, but I should get it done, in and amongst.
Funding for some of the genomics group (nice day today) for Q1 (differs somewhat from the Burrill list) -
ABSC -
"At December 31, 1999, we held cash, cash equivalents and investment securities available-for-sale of $36.6 million and working capital of $25.8 million.
In February 2000, we completed a private placement of 1.8 million shares of newly issued common stock to selected institutional and other accredited investors. The purchase price was $42.00 per share, resulting in net proceeds of approximately $71 million."
INCY - "Subsequent to December 31, 1999, the Company raised additional funds in two financing transactions. In February 2000, the Company issued $200.0 million aggregate principal amount of 5.5% convertible subordinated notes due 2007 in a private placement, resulting in net proceeds of approximately $196.8 million. Beginning May 15, 2000, the notes are convertible at the option of the note holders into the Company's common stock at an initial conversion price of $134.839 per share, subject to adjustment. Also in February 2000, the Company issued 2,000,000 shares of its common stock in a private placement, for an aggregate purchase price of $422.0 million. Net proceeds from the sale of those shares were $398.3 million."
AFFX - "As of December 31, 1999, Affymetrix had cash, cash equivalents, and available-for-sale securities of approximately $225.0 million. In February 2000, the Company sold an additional $225 million of subordinated convertible notes in a private placement. These notes bear interest at 4.75% and mature in 2007"
MLNM - "As of December 31, 1999, we had approximately $261.7 million in cash, cash equivalents and marketable securities, an increase of $70.8 million from December 31, 1998.
In January 2000, we completed a sale, pursuant to Rule 144A of the Securities Act of 1933, of $400 million of 5.5% Convertible Subordinated Notes due January 15, 2007. The Notes are convertible into shares of our common stock at any time prior to maturity at a price equal to $168.28 per share, subject to adjustment..."
CRA - -"March 3rd PE Corp. today announced the exercise by its underwriters of an over-allotment option to purchase 570,000 shares of Celera Genomics common stock associated with its follow-on stock offering announced March 1, 2000.
Including the over-allotment, the public offering totaled 4,370,000 shares at $225.00 per share, with net proceeds expected to be approximately $944 million.
Jan. 31, 2000--PE Corporation announced today the filing of a registration statement with the Securities and Exchange Commission in connection with a follow-on public offering of 1.615 million shares of its Celera Genomics Group Common Stock
The company has also granted the underwriters a 15 percent over-allotment option. The number of shares to be sold does not reflect the previously announced two-for-one stock split of Celera Genomics Group Common Stock which is to be effective February 18"
CRGN - (did they split on Mar 31st ?)
"Feb. 14 , a genomics based drug discovery and development company, announced today the sale of an additional $25 million aggregate principal amount of convertible subordinated debentures to certain initial purchasers. The initial purchasers exercised the over-allotment option granted to them pursuant to CuraGen's recent offering and sale to such initial purchasers of convertible subordinated debentures. Total gross proceeds from this offering equal $150 million"
(held $76m cash in Dec 99)
GLGC - (near zip cash prior to ...)
"On February 1, 2000, we completed a public offering of our common stock at $56.00 per share. We sold 4,680,000 shares, and received net proceeds of approximately $247.5 million."
HGSI - (? c. $250m cash prior to...)
"March 10 /PRNewswire/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI - news) announced today the closing of its private placement of $300 million principal amount of 3 3/4% Convertible Subordinated Notes Due 2007. The Notes are convertible into Human Genome Sciences Common Stock at a price equal to $219.00 per share
Jan. 27 /PRNewswire/ HGSI announced today the private placement of $150 million principal amount of 5% Convertible Subordinated Notes Due 2007, anticipated to close on February 1, 2000. These Notes are convertible into HGS Common Stock at a price equal to $225.00 per share. HGS has granted the initial purchaser of the Notes a 30-day right to purchase an additional $75 million principal amount of Notes on the same terms and conditions."
On January 31, 2000, HGS common stock will begin trading on a two-for-one split basis. On that same date, the conversion price of these 5% Convertible Subordinated Notes Due 2007 will be adjusted to $112.50 per share. |
